3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Multiple Myeloma
63
Precursor Cell Lymphoblastic Leukemia-Lymphoma
27
Burkitt Lymphoma
25
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
11
Lymphoma, Mantle-Cell
7
Leukemia, Biphenotypic, Acute
7
Recurrence
6
Immunoglobulin Light-chain Amyloidosis
6
Vomiting
5
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma
5
Leukemia, Myeloid, Acute
5
Carcinoma, Non-Small-Cell Lung
5
Smoldering Multiple Myeloma
4
Neoplasm Metastasis
4
Nausea
4
Leukemia
4
Hodgkin Disease
4
Breast Neoplasms
4
Blast Crisis
4
Plasmacytoma
3
Ovarian Neoplasms
3
Neoplasms
3
Myelodysplastic Syndromes
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Lung Neoplasms
3
Leukemia, Plasma Cell
3
Interventions
dexamethasone acetate
1
dexamethasone 21-phosphate
1
Etoricoxib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Somatoform Disorders
×
dexamethasone 21-phosphate
×
Clear all
NCT03348696
2020-01-09
REaCT-TAPS
Ottawa Hospital Research Institute
Phase 4
Completed
124 enrolled